Zobrazeno 21 - 30
of 38
pro vyhledávání: ''
Publikováno v:
BMC Pharmacology & Toxicology
Background Polymorphisms of Arylamine N-acetyltransferase (NAT) that contribute to diverse susceptibilities of some autoimmune diseases are also linked to the metabolism of several drugs including sulfasalazine (SSZ). The aim of this study was to inv
Autor:
Warren M. Zapol, Peter Brouckaert, Sara Vandenwijngaert, Wolfgang S. Lieb, Ana C. Dordea, Emmanuel S. Buys, Robert E. Tainsh, Stefan Münster
Publikováno v:
BMC Pharmacology & Toxicology
Background The nitric oxide (NO)-soluble guanylate cyclase (sGC)cyclic guanosine 3’5’-monophosphate (cGMP) pathway regulates intraocular pressure (IOP). Preclinical and clincial studies have demonstrated the ability of NO-donor compounds to lower
Publikováno v:
BMC Pharmacology & Toxicology
Background Cytotoxic chemotherapy is the standard treatment in most cancer patients with advanced stage. However, many patients suffer from severe side effects even if the anti-cancer treatment is effective. There is no established strategy to preven
Publikováno v:
BMC Pharmacology & Toxicology
Background Pulmonary hypertension is a disabling disease associated with high mortality [1,2]. Riociguat (under review for the treatment of pulmonary hypertension) stimulates soluble guanylate cyclase, which plays an important role in the regulation
Autor:
Adeline Rollin-Sillaire, Emilie Le Rhun, Xavier Delbeuck, Florence Pasquier, Marie-Anne Mackowiak, Marianne Pollet, Marie-Pierre Noel, Thierry Facon, P. Lenfant, Xavier Leleu
Publikováno v:
BMC Pharmacology & Toxicology
Background There are many reports of cognitive dysfunction in patients receiving chemotherapy or targeted therapies. Many antineoplastic agents may be involved in the condition also known as “chemo brain” or “chemo fog”. Case presentation Two
Autor:
Hirofumi Tachibana, Motofumi Kumazoe
Publikováno v:
BMC Pharmacology & Toxicology
Background EGCG ((−)-epigallocatechin-3-O-gallate), a polyphenol in green tea, induces apoptotic cell death in cancer cells without affecting normal cells and several clinical trials have been carried out to evaluate its potential value [1,2]. 67kD
Publikováno v:
BMC Pharmacology & Toxicology
Background Riociguat, an oral soluble guanylate cyclase (sGC) stimulator, is currently being investigated for the treatment of pulmonary hypertension. Riociguat has a novel dual mode of action, directly stimulating sGC, independent of nitric oxide (N
Publikováno v:
BMC Pharmacology & Toxicology
Background Nitric oxide (NO) is a potent biological mediator and plays an important role in cardiovascular homeostasis. Here it activates the soluble guanylyl cyclase (sGC) that synthesizes cGMP. The intracellular second messenger cGMP regulates vasc
Publikováno v:
BMC Pharmacology & Toxicology
Background Olanzapine use has been reported during pregnancy and breastfeeding, but there are no controlled clinical trials assessing the safety of olanzapine exposure to infants and fetuses. The purpose of this report was to review and analyze prosp
Publikováno v:
BMC Pharmacology & Toxicology
Riociguat is the first oral soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension. This pooled analysis of two non-randomized, non-blinded, observational studies evaluated the pharmacokinetics of riociguat and its metabolit